StreetAlpha
13F holdings · Q3 2026

Ally Bridge Group (NY)

New York, NY · files as Ally Bridge Group (NY) LLC
Know the moment Ally Bridge Group (NY) filesYou follow Ally Bridge Group (NY) An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1822947

Ally Bridge Group (NY) reported 14 stocks worth $43.4M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are EWTX (17.3%), PMN (15.5%) and NERV (12.8%). Compared with Q2 2026, the fund opened new positions in AMLX, STTK and OBX, added to EWTX, trimmed NERV, EPRX and AVTX and sold out of TRAX, AXSM and WHWK.

Latest filing: what Ally Bridge Group (NY) did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
4 new1 added6 trimmed13 sold outBought about $18.6M · sold about $45.7M
New 4
Added 1
Trimmed 6
See all 6 →
Sold out 13
See all 13 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$43.4M−44.1% vs last quarter · $76M including options
Stocks held144 new · 13 sold out
Top 5 weight67.6%very concentrated
Turnover148%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
EWTX
Edgewise Therapeutics Inc
$7.5M17.3%185K+102K (+123%)6 of 8
2
PMN
Promis Neurosciences Inc
$6.7M15.5%620KNo change4 of 8
3
NERV
Minerva Neurosciences Inc
$5.5M12.8%1.7M−520K (−24%)4 of 8
4
AMLX
Amylyx Pharmaceuticals Inc
$5.3M12.2%182KNew position2 of 8
5
STTK
Shattuck Labs Inc
$4.3M9.8%625KNew position1 of 8
6
OBX
Obsidian Therapeutics Inc
$4.2M9.6%302KNew position1 of 8
7
ANTX
AN2 Therapeutics Inc
$2.8M6.5%526KNo change3 of 8
8
EPRX
Eupraxia Pharmaceuticals Inc
$2.1M4.8%231K−21K (−8%)5 of 8
9
AVTX
Avalo Therapeutics Inc
$2.1M4.8%134K−16K (−10%)3 of 8
10
IVA
Inventiva SA
$839K1.9%227K−408K (−64%)4 of 8
🔒 4 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
TRAX
First Tracks Biotherapeutics
$5.7M284K
AXSM
Axsome Therapeutics Inc
$4M16K
WHWK
Whitehawk Therapeutics Inc
$3.7M818K
CLYM
Climb Bio Inc
$3.2M249K
KURA
Kura Oncology Inc
$3.2M290K

🔒 Free account: see all 13.

Options

valued at the underlying shares
StockTypeValueSharesChange
DFTX
Definium Therapeutics Inc
Call$15.2M400K0
ABVX
Abivax SA
Call$12.4M125K0
ALMS
Alumis Inc
Call$3M400K+400,000
CMPX
Compass Therapeutics Inc
Call$2.1M2M+2,000,000

Reported value

last 8 quarters
$117MQ4 '24
$111MQ1 '25
$120MQ2 '25
$119MQ3 '25
$63MQ4 '25
$101MQ1 '26
$77.6MQ2 '26
$43.4MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Ally Bridge Group (NY) 13F FAQ

What does Ally Bridge Group (NY) own?

Ally Bridge Group (NY) reported 14 stocks worth $43.4M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are EWTX (17.3%), PMN (15.5%) and NERV (12.8%). The table above lists every position in the filing (the top 10 without an account).

What did Ally Bridge Group (NY) buy and sell in Q3 2026?

Compared with Q2 2026: 4 new positions, 1 added to, 6 trimmed and 13 sold out. New positions include AMLX, STTK and OBX. It sold all of TRAX, AXSM and WHWK.

When will Ally Bridge Group (NY) file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Ally Bridge Group (NY)'s portfolio worth?

The Q3 2026 filing reports $43.4M in US stocks ($76M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.